Data presented at the 2008 Genitourinary Cancers Symposium
VANCOUVER, Feb. 15 /PRNewswire/ - OncoGenex Technologies Inc. announced today that the Company's lead cancer drug candidate, OGX-011, also referred to as custirsen, was well-tolerated in combination with either docetaxel or mitoxantrone administered as second-line chemotherapy in patients with hormone refractory prostate cancer. Additionally, patients treated with second-line chemotherapy plus OGX-011 showed ongoing survival durations better than results published with chemotherapy alone. Phase 2 data were presented today at the 2008 Genitourinary Cancers Symposium. OncoGenex and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) are collaborating on development of OGX-011.
According to data presented by Dr. Fred Saad, Professor of
Surgery/Urology at the University of Montreal, the primary objectives of
safety and tolerability were achieved in the 42 patients evaluated in the
study. In addition, encouraging outcomes were observed with OGX-011
administered in combination with second-line chemotherapy.
- More chemotherapy than expected was safely administered to and
tolerated by patients when OGX-011 was combined with second-line
chemotherapy: Patients received a median of 6 cycles of mitoxantrone
or 7.5 cycles of docetaxel as second-line chemotherapy. These data
compare favorably with published reports documenting a median of
3-4 cycles with second-line chemotherapy alone.
- Survival was better than expected based on previously published
reports: With a median follow-up of 13.3 months following second-line
chemotherapy, approximately 30 percent of patients in both arms have<
|SOURCE OncoGenex Technologies Inc.|
Copyright©2008 PR Newswire.
All rights reserved